New drug combo targets tough blood cancers
NCT ID NCT04493138
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 39 times
Summary
This study tests whether combining two drugs, azacitidine and quizartinib, can help people with myelodysplastic syndromes or related blood cancers that have specific genetic changes (FLT3 or CBL mutations). The trial involves 30 adults and aims to find the best dose and see how well the combination works at controlling the disease. It is still in early stages, so the main focus is on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
azacitidine and quizartinib
What this could lead to
If successful, this combination could offer a new treatment option for people with certain genetic mutations in myelodysplastic syndromes and related blood cancers.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. Side effects from the drug combination are possible and are being closely monitored.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.